ELC-100 (AdVince)

About Elicera Therapeutics

Elicera Therapeutics is a clinical-stage biotech focused on developing potent cell and gene therapies for aggressive and recurrent cancers, with a core mission to conquer solid tumors. Its foundational achievement is the patented iTANK platform, which enhances CAR T-cells to recruit the patient's own immune system, creating a multi-targeted attack. The company's strategy leverages a dual business model: advancing four internal therapeutic programs (two CAR T-cell and two oncolytic virus candidates) and generating near-term value through non-exclusive out-licensing of the iTANK technology. Recent recognition of its scientific founder as 'Cancer Researcher of the Year 2026' underscores the quality of its research foundation.

Therapeutic Areas